[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colon-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colon-neoplasm":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,57,90,113,153,189,211,259,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100627590","liquid-biopsy-and-machine-learning-for-early-colorectal-cancer-adenomas-lynch-cancers-and-residual-disease-detection-100627590",false,"NCT07450612","Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection","BEACON","Inclusion Criteria:\n\n* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.\n* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment\n\nExclusion Criteria:\n\n* Lack of informed consent\n* Inflammatory bowel disease",true,"ALL","18 Years",{"count":20,"type":21},1200,"ESTIMATED","OBSERVATIONAL","This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Colorectal Cancer","Adenoma Colon","Adenoma Colon Polyp","Colon Adenoma","Colo-rectal Cancer","Colon Disease","Colon Neoplasm","Lynch Syndrome","Lynch Syndrome I","Lynch Syndrome II","Lynch Syndrome I (Site-specific Colonic Cancer)","LYN Gene Mutation","Mismatch Repair Deficiency","Mismatch Repair Gene Mutation","MLH1 Gene Mutation","MSH2 Gene Mutation","MSH6 Gene Mutation","PMS2 Gene Mutation","EPCAM Gene Mutation","RECRUITING","2026-02-27",{"date":47,"type":48},"2026-03-04","ACTUAL",{"date":50,"type":48},"2024-01-01",{"date":52,"type":21},"2031-08-15",{"name":54,"class":55},"San Raffaele University","OTHER",4,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100625815","exploration-of-circulating-micrornas-as-biomarkers-of-chemo-induced-peripheral-neuropathy-a-study-in-cancer-patients-100625815","NCT07427537","Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients","miR-CIPN#1","Inclusion Criteria:\n\n* Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or\n* Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.\n\nExclusion Criteria:\n\n* Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),\n* History of stroke,\n* Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15\u002F100),\n* Pain (NRS ≥ 4\u002F10),\n* Pregnant or breastfeeding women,\n* Patients under guardianship, curatorship, deprived of liberty, or under legal protection",{"count":65,"type":21},90,"INTERVENTIONAL",[68],"NA","This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).",[71,31,72],"Cancer, Lung","Neuropathy;Peripheral",[74,75,76,77,78,79],"biomarker","colorectal cancer","lung cancer","oxaliplatin","paclitaxel","chemotherapy-induced peripheral neuropathy","2026-02-16",{"date":82,"type":48},"2026-02-23",{"date":84,"type":48},"2026-01-29",{"date":86,"type":21},"2028-07-31",{"name":88,"class":55},"University Hospital, Clermont-Ferrand",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":66,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":89},"100465814","phase-4-tranexamic-acid-during-colonic-endoscopic-resection-procedures-100465814","NCT05345613","Tranexamic Acid During Colonic Endoscopic Resection Procedures","Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding","Inclusion Criteria:\n\n* Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* patients with histories of allergic reactions to TXA\n* history of seizures\n* pregnancy",{"count":98,"type":21},200,[100],"PHASE4","Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.",[31],"2026-01-10",{"date":105,"type":48},"2026-01-13",{"date":107,"type":48},"2022-05-01",{"date":109,"type":21},"2026-10-01",{"name":111,"class":112},"Assaf-Harofeh Medical Center","OTHER_GOV",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":66,"phases":123,"briefSummary":124,"conditions":125,"keywords":137,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":89},"100566245","sentinel-node-and-organ-sparing-surgery-in-stage-i-colon-carcinoma-100566245","NCT06652672","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma (SENTRY Trial)","SENTRY","Inclusion Criteria:\n\n* Oral and written informed consent (IC)\n* Aged 18 years and older\n* Fit for both organ-sparing surgery and colectomy\n* Pathologically confirmed T1-2 adenocarcinoma of the colon following R0, R1, or Rx endoscopic resection with an estimated LNM risk \\>15% (Table 5.2.2. in module 5.2 of the Dutch CRC guideline); or a lesion macroscopically suspected to be (deep-invasive) T1 colon cancer, measuring \\\u003C40 mm, for which wedge resection is considered the most suitable local resection technique as recommended by the MDT\n* The resection scar after local excision is expected to be clearly recognized at endoscopy, either by a tattoo or by detecting a scar in the colorectal segment where no other polypectomies were performed\n* Lesion located \\>25cm from the anus based on endoscopic measurement, or above sigmoid take-off\n\nExclusion Criteria:\n\n* Patients who opt for active follow-up instead of surgery following shared decision-making\n* Distant metastasis\n* Lynch syndrome\n* Another active malignancy requiring palliative treatment at the time of colon cancer diagnosis\n* Previous colorectal cancer within the last 5 years\n* Tumours that comprised \\>50% of the colon circumference before resection\n* Tumours involving the ileocaecal valve\n* Pregnancy, lactation or a planned pregnancy during the course of the study\n* Known allergy to any of the compounds used for SLN identification (ICG, Iodine or Sodium iodide)\n* Previous colonic surgery (excluding appendectomy)\n* Contra-indication for laparoscopic or robotic surgery\n* Severe kidney- or liver failure\n* Hyperthyroidism or an autonomously functioning thyroid adenoma",{"count":122,"type":21},341,[68],"The aim of this study is to reduce the need for colectomy and its' associated morbidity and mortality in patients with pT1-2 colon carcinoma after endoscopic resection and an estimated lymph node metastasis (LNM) risk of \\>15%, or with macroscopically suspected T1 tumors, by performing an endoscopic-assisted laparoscopic\u002Frobotic wedge resection of the tumor or scar, along with sentinel node (SLN) biopsy using indocyanine green (ICG). This intervention will be compared to the standard-of-care segmental resection using a partially randomized patient preference design. The primary outcome is the 3-year recurrence rate.",[126,127,128,129,130,31,131,132,133,134,135,136],"Colon Cancer","Colon Adenocarcinoma","Sentinel Lymph Node","Sentinel Lymph Node Biopsy","Colon Neoplasms","Fluorescence","Fluorescence Guided Surgery","Fluorescence Laparoscopy","Fluorescence-guided Resection","Colon Surgery","Indocyanine Green (ICG)",[138,131,139,140,141,142,143],"Colon cancer","Sentinel lymph node","Indocyanine green (ICG)","Organ sparing surgery","Organ preserving surgery","Local resection","2025-11-17",{"date":146,"type":48},"2025-11-20",{"date":148,"type":48},"2024-12-12",{"date":150,"type":21},"2032-12-12",{"name":152,"class":55},"Meander Medical Center",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":66,"phases":162,"briefSummary":164,"conditions":165,"keywords":172,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100565283","phase-2-encorafenib--cetuximab-beyond-progression-in-combination-with-folfiri-in-patients-with-braf-v600e-mutated-metastatic-colorectal-cancer-progressing-on-encorafenib--cetuximab-100565283","NCT06640166","Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","ECLYPse","Inclusion Criteria:\n\n* written informed consent to study procedures;\n* age ≥ 18 years;\n* histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma;\n* radiological evidence of metastatic disease;\n* evidence of measurable disease according to RECIST 1.1 criteria;\n* presence of BRAF V600E mutation in tumor tissue (primary CRC and\u002For related metastasis) as previously determined by a local assay at any time prior to screening (only PCR and NGS-based local assays results will be acceptable);\n* disease progression while on treatment with EC received in 2nd line setting\n\n  * EC administered after disease relapse during treatment or within 6 months following adjuvant therapy will be second line;\n  * maintenance therapy given in the metastatic setting after a first line doublet or triplet chemotherapy will not be considered a separate regimen;\n* best response to previous treatment with EC: CR, PR or SD lasting for at least 3 months.\n* patient fit for a subsequent treatment line with FOLFIRI. Patients exposed to irinotecan and fluoropyrimidines during previous line for metastatic disease are eligible, provided that the patient has recovered from G3 toxicity;\n* life expectancy ≥ 3 months;\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤1.\n* Adequate bone marrow function at screening:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL;\n  * Platelets ≥ 100 × 10\\^9\u002FL;\n  * Hemoglobin ≥ 9.0 g\u002FdL;\n  * Note: Transfusions will be allowed to achieve this. Transfusions will be permitted provided that the patient has not received more than 2 units red blood cells in the prior 4 weeks to achieve this criteria.\n* Adequate renal function at screening: serum creatinine ≤ 1.5 × upper limit of normal (ULN), or calculated by Cockroft-Gault formula, or directly measured creatinine clearance ≥ 50 mL\u002Fmin at screening.\n* Adequate hepatic function at screening:\n\n  * serum total bilirubin ≤ 1.5 × ULN;\n  * alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN in presence of liver metastases.\n* Adequate cardiac function characterized by the following at screening: QT interval corrected for heart rate using Fridericia's formula (QTcF) value ≤480 msec.\n* Availability of treatment-naïve, archival FFPE tumor tissue sample.\n* Ability to take oral medications.\n* Male subjects with female partners of childbearing potential must be willing to use adequate contraception, starting with the first dose of study therapy through 180 days after the last dose of treatment. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n* Women of childbearing potential must have a negative blood or urine pregnancy test at the baseline visit.\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study starting with the first dose of study therapy through 180 days after the last dose of treatment. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n* Will and ability to comply with the protocol.\n\nExclusion Criteria:\n\n* patients experiencing PD as best response to EC;\n* patients with specific BRAFi\u002FAntiEGFR contraindications;\n* patients with specific irinotecan or fluoropyrimidines contraindications;\n* patients with DPYD deficiency;\n* life expectancy ≤3 months;\n* ECOG PS \\>1.\n* Any of the following in the 6 months prior to treatment start: myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft \\[CABG\\], coronary angioplasty or stenting), congestive heart failure (≥ New York Heart Association Classification Class II), serious cardiac arrhythmia (except atrial fibrillation and appropriately controlled paroxysmal supraventricular tachycardia), cerebrovascular accident, symptomatic pulmonary embolism.\n* Congenital long QT syndrome.\n* Impaired gastrointestinal function or disease that may significantly alter the absorption of encorafenib (uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption).\n* Uncontrolled coagulopathy.\n* Patients has a known history of Gilbert's syndrome or is known to have any of the following genotypes: UGT1A1\\*6\u002F\\*6, UGT1A1\\*28\u002F\\*28, or UGT1A1\\*6\u002F\\*28.\n* Active infection requiring systemic therapy.\n* Known history of acute or chronic pancreatitis.\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).\n* Symptomatic brain metastasis or leptomeningeal disease. Prior hypersensitivity or toxicity that would suggest an inability to tolerate administration of the planned dose of investigational products.\n* Residual CTCAE \\> Grade 2 toxicity from any prior anticancer therapy, with the exception of alopecia or neuropathy.\n* Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies, including current treatment with a non-topical medication known to be a strong inhibitor of cytochrome P450 (CYP) 3A4 ≤ 1 week prior to the start of study treatment.\n* Concomitant use of St. John's Wort (hypericum perforatum).\n* Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient an inappropriate candidate for the study.\n* Concurrent or previous other malignancy within the past 3 years, with the exception of effectively treated squamous cell or basal cell skin cancer, melanoma in situ, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, carcinoma in situ of the colon or rectum, or other noninvasive or indolent malignancy without Sponsor approval.\n* Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study and until 180 days after the last trial treatment.",{"count":161,"type":21},25,[163],"PHASE2","The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.",[166,167,168,169,170,25,126,127,171,31],"Colorectal Carcinoma","Colorectal Neoplasms","Colorectal Tumor","Colorectal Adenocarcinoma","Colorectal Cancer (CRC)","Colon Carcinoma",[173,174,175,176,75,177,178],"BRAF","V600E","encorafenib","cetuximab","FOLFIRI","BRAF V600E","2025-02-11",{"date":181,"type":48},"2025-02-12",{"date":183,"type":48},"2024-06-03",{"date":185,"type":21},"2026-06-30",{"name":187,"class":55},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",3,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":66,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100433132","phase-2-mesalamine-for-colorectal-cancer-prevention-program-in-lynch-syndrome-100433132","NCT04920149","Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","MesaCAPP","Inclusion Criteria:\n\n* Proven tumor-free (including patients in which the polyps are removed endoscopically) carriers of a germline pathologic mutation in one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6\n* Male or female subjects with the age of 30 years or older\n* Females who have been post-menopausal more than one (1) year or females of childbearing potential using a highly efficient method of contraception with less than 1% failure rate (i.e. oral hormonal contraceptives, hormone implants, hormone injections, sterilization, hormonal or copper intrauterine device, sterilized\u002Fvasectomized partner, or diaphragm in combination with a condom, spermicide or birth control pills) or should agree to abstain from heterosexual activity during treatment period. Females of childbearing potential must have a negative pregnancy test at screening and before randomization.\n* Signed written informed consent prior to inclusion in the study\n\nExclusion Criteria:\n\n* Presence of colorectal endoscopically non-removable benign neoplasia (patient can be included if the adenoma is removed)\n* Carriers of germline mutations in PMS2\n* Patients with history of stage 3 and 4 CRC are excluded\n* Presence of metastatic disease\n* Regular use of aspirin\u002FASA: daily use of ≥100mg in more than 3 continuous months within the last year\n* Regular use of NSAIDs or COX-2 inhibitors: daily use in more than 3 continuous months within the last year\n* Hypersensitivity to 5-ASA\n* Patients after any subtotal or total colectomy\n* Colorectal surgery within the previous 6 months\n* Unwillingness to participate or who is considered incompetent to give an informed consent\n* Pregnant or breastfeeding women\n* Participation in another clinical study investigating another IMP within 1 month prior to screening\n* Renal insufficiency (GFR \\\u003C30ml\u002Fmin\u002F1.73m2)\n* Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)\n* Current or history of serious psychiatric disorder or alcohol\u002Fdrug abuse that in the opinion of the investigator may impact the assessment of IMP safety and efficacy or protocol adherence\n* Prior history of myocarditis or pericarditis. Other severe acute or chronic medical condition such as severe chronic lung (COPD, including asthma, kidney and heart diseases) or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or ability to comply with study procedures, investigational product administration and, in the judgment of the investigator, would make the subject inappropriate for entry into this study","30 Years",{"count":198,"type":21},150,[163],"Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.",[32,126,31],{"date":203,"type":48},"2024-12-17",{"date":205,"type":48},"2022-03-21",{"date":207,"type":21},"2045-09-30",{"name":209,"class":55},"Ann-Sofie Backman",8,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":66,"phases":220,"briefSummary":221,"conditions":222,"keywords":226,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100564575","evaluating-the-impact-of-financial-navigation-on-financial-catastrophe-and-distress-for-cancer-care-100564575","NCT06630962","Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care","Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care: A Randomized Control Trial- COST-FIN","COST-FIN","Inclusion Criteria:\n\n* Age 18 years and older\n* Recently diagnosed with breast, colorectal or prostate cancer within 6 weeks of presentation at the study site\n* Have not received definitive chemotherapy, radiotherapy, or undergone major surgery (diagnostic or temporary interventions, such as excisional biopsy or temporary colostomy may still enroll)\n* Candidate for definitive cancer treatment\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Has initiated definitive cancer treatment at the study site or elsewhere in the past\n* Only receiving best supportive care",{"count":98,"type":21},[68],"The goal of this study is to investigate the effectiveness of a structured financial navigation program in reducing financial catastrophe and financial distress for cancer patients in Nigeria.\n\nThe main study questions being investigated are:\n\n1. If a financial navigation program can effectively and significantly reduce financial catastrophe and distress for cancer patients in Nigeria?\n2. If a financial navigation program is financially sustainable and cost-effective for cancer centers in Nigeria?\n\nParticipants will be required to:\n\n1. Complete surveys about their demographics, clinical history, and socioeconomic status\n2. Complete questionnaires about their quality of life and psychological wellbeing\n3. Report all costs related to their cancer care\n\nInvestigators will compare participants in the financial navigation program and those not in the financial navigation program to identify potential differences in catastrophic health expenditure and financial distress.",[223,224,31,225],"Breast Neoplasm","Prostate Neoplasm","Rectal Neoplasm",[227,228,229,223,224,31,225,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248],"Financial Navigation","Financing Cancer Care","Nigeria","Health Insurance","Randomized Control Trial","Healthcare Cost","Health Expenditure","Financial Risk Sharing","Universal Health Insurance","National Health Insurance Scheme","Catastrophic Health Spending","Financial Distress","Sub-Saharan Africa","Health Plan Implementation","Global Health","Healthcare Economics and Organizations","Clinical Oncology","Cancer Care Facilities","Surgical Oncology","Global Burden of Disease","Social Determinants of Health","Health Impact Assessment","2024-10-04",{"date":251,"type":48},"2024-10-08",{"date":253,"type":48},"2024-07-15",{"date":255,"type":21},"2026-09",{"name":257,"class":55},"Northwestern University",2,{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":66,"phases":269,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":277,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":89},"100563393","a-novel-adaptive-anastomotic-technique-for-left-sided-colonic-resection-100563393","NCT06615583","A Novel Adaptive Anastomotic Technique for Left-sided Colonic Resection","A Novel Adaptive Anastomotic Technique for Left-sided Colonic and Rectal Resection: a Pilot, Single-center, Prospective, Case-series Study","NOVA","Inclusion Criteria:\n\n* Patients aged equal or more than 18 years old, both men and women.\n* Patients with a proven diagnosis of sigmoid colon or high rectal tumors requiring anterior rectal resection as procedure of choice (colorectal cancer or benign polyps), as confirmed by radiological and histological exams.\n* Patient indicated to minimally invasive or open sigmoid or high rectal resection.\n\nExclusion Criteria:\n\n* Patients with pre-existing health conditions requiring surgery, such as intestinal obstruction or perforation, local or systemic infections, peritonitis, or intestinal ischemia. Patients with intraoperative evidence of any of these conditions will be withdrawn from the study.\n* Patients with preoperative evidence of distal metastasis. Patients with intraoperative evidence of distal metastasis or peritoneal carcinosis will be withdrawn from the study.\n* Patients with documented intestinal or anal stenosis or other obstructions distal to the anastomosis. Patients with intraoperative evidence of intestinal or anal stenosis will be withdrawn from the study.\n* Patients who received radiation therapy to organs in abdomen or pelvis unrelated to current colorectal condition.\n* Patients who are unable or received contraindication for the preoperative mechanical preparation. Patients with a preoperative evidence or suspicion of incomplete colon cleansing will be withdrawn from the study.\n* Patients indicated to defunctioning stoma. Patients requiring diverting stoma as for intraoperative indication will be withdrawn from the study.\n* Patients with an anastomosis in rectum below the peritoneal reflection and\u002For another procedure of choice than high anterior resection.\n* Any condition that, in the opinion of the investigator, may interfere with the study conduction. In particular, any condition which can cause significant alteration of colonic wall thickness such as chronic and repeated infection which may impair the use of C-REX.",{"count":268,"type":21},30,[68],"The goal of this pilot clinical trial is provide preminary evidence of the effectiveness of the C-REX device, developed by CarpoNovum AB, in preventing anastomotic leak and improving anastomosis healing after sigmoid or high rectal resection in patients with colon neoplasia. The primary aim of the study is to evaluate the rate of anastomotic leak in patients receiving the study device within 90 days from the surgical procedure.",[31],[273,274,275,276],"Colorectal neoplasms","Colorectal anastomosis","Anastomotic leak","Surgical device","NOT_YET_RECRUITING","2024-09-24",{"date":280,"type":48},"2024-09-26",{"date":282,"type":21},"2024-10-01",{"date":284,"type":21},"2026-03-31",{"name":286,"class":55},"Istituto Clinico Humanitas",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":66,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":89},"100509512","phase-2-induction-chemotherapy-combined-with-neoadjuvant-immunotherapy-for-mss-colon-cancer-100509512","NCT05914389","Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer","Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer: a Prospective Single-center Multi-arm Open-label Randomized Phase II Study","ICONIC","Inclusion Criteria:\n\n* Age ≥18 years old and ≤75 years old.\n* Pathologically diagnosed MSS or pMMR-type colon adenocarcinoma.\n* The lower edge of the tumor is more than 12cm from the anus as measured by colonoscopy and the lower edge of the tumor cannot be directly palpated during rectal examination.\n* Enhanced CT stage T3\u002F4 or T1-4N+ without multiple primary tumors or distant metastasis.\n* Life expectancy is expected to be more than 1 year.\n* First diagnosis, no previous anti-tumor treatment received, and no chemotherapy contraindications.\n* Informed consent, able to understand the study protocol and willing to participate in the study, and will provide written informed consent.\n\nExclusion Criteria:\n\n* Refused to participate in this study.\n* Multifocal colorectal cancer.\n* History of malignant tumors, except for basal cell carcinoma, papillary thyroid carcinoma, and various in situ cancers.\n* Cannot tolerate chemotherapy, such as but not limited to bone marrow suppression.\n* Acute exacerbation of important organ diseases (such as but not limited to COPD, coronary heart disease, and renal insufficiency) and\u002For severe acute infectious diseases (such as but not limited to hepatitis, pneumonia, and myocarditis), ASA score \\> 3 points.\n* Mental disorders, illiteracy, or language communication barriers that prevent the understanding of the study protocol.\n* Tumor obstruction or high risk of obstruction, bleeding, and\u002For perforation.\n* Peripheral sensory neuropathy, unable to receive oxaliplatin-based chemotherapy.\n* Pregnancy or lactation.\n* Unable to undergo enhanced CT examination or having comorbidities requiring the use of glucocorticoid therapy.\n* Continuous use of glucocorticoids for more than 3 days within 1 month prior to signing the informed consent form.\n* CT or MRI in the mid-sagittal plane shows that the lower border of the tumor is below the line connecting the sacrococcygeal promontory and the upper border of the pubic symphysis.\n* Other situations in which the researcher deems unsuitable for this study.","75 Years",{"count":297,"type":21},100,[163],"This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.",[31],"2023-08-06",{"date":303,"type":48},"2023-08-08",{"date":305,"type":21},"2023-08",{"date":307,"type":21},"2030-08",{"name":309,"class":55},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]